Cebranopadol as a Novel Promising Agent for the Treatment of Pain
Wojciech Ziemichód, Jolanta H. Kotlińska, Ewa Gibuła‐Tarłowska, Natalia Karkoszka, Ewa Kędzierska
Abstract
Opioids are used to treat pain, but despite their effectiveness, they possess several side effects such as respiratory depression, tolerance and physical dependence. Cebranopadol has been evaluated as a solution to this problem. The compound acts on the mu opioid receptor and the nociceptin/orphanin receptor and these receptors co-activation can reduce opioid side-effects without compromising analgesia. In the present review, we have compiled information on the effects of cebranopadol, its pharmacokinetics, and clinical trials involving cebranopadol, to further explore its promise in pain management.
Topics & Concepts
Nociceptin receptorOpioidNOPMedicineReceptorPharmacologyDepression (economics)Clinical trialPharmacokineticsAnesthesiaOpioid peptideInternal medicineEconomicsMacroeconomicsNeuropeptides and Animal PhysiologyPain Mechanisms and TreatmentsPharmacological Receptor Mechanisms and Effects